30 results about "Endorphins" patented technology

The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning. A novel understanding of the bimodal opioid modulation of pain, and its impact, through serotonergic, dopaminergic, epinephrinergic, and norepinephrinergic processes, on hedonic tone, leads directly to new generation pharmaceutical formulations that are remarkably safe and effective for the treatment of a wide variety of Distress Dysfunctions, including anxiety, depression, anger, insomnia, mood disorders, eating disorders, sexual problems, pain, substance and behavioral addictions, gastrointestinal disorders, autistic spectrum disorders, attention-deficit and hyperactivity disorders, and other emotional and physical distress disorders. The foundation of this discovery is the power of Receptor Switchers, such as ultra-low-dose and very-low-dose opioid antagonists and GM1 ganglioside attenuators, in blocking acute and protracted excitatory opioid receptor signaling. Co-administration of Receptor Switchers with Endorphin Enhancers, such as specific cAMP PDE inhibitors and excitatory amino acids, is an excellent formulation for restoring healthy homeostatic balance to the endogenous opioid system, using the body's endorphins to reduce emotional and physical distress, and through synergistic and homeostatic processes, restoring positive hedonic tone. The addition of Synergistic Enhancers, such as amino acids, SSRI and SNRI agents, and non-opioid analgesics, as well as Exogenous Opioids, enhances and prolongs these therapeutic benefits. The novel principles discovered by this invention also teach a new generation of safe and effective formulations for the treatment of respiratory conditions, neuropathy, and nociceptive pain.

Placement of a silicone tube in the cerebral aqueduct and the transmission of red light through it, resulting in the irradiation and consequent biostimulation of the adjacent periaqueductal gray, thereby causing the release of endorphins therefrom and pain relief.

The subject of the invention is the use of at least one compound chosen from β-endorphin and β-endorphin-mimetic agents on the keratinocytes of the skin, for example in a cosmetic composition to enhance the barrier function of the skin, enhance its resistance to stress and in particular to pollution. It also relates to a method of cosmetic treatment for enhancing the barrier function and / or the moisturization of the skin and / or mucous membranes.

The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and / or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion to apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and / or nociceptin.

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and / or nociceptin.

The invention provides a smoke abatement tea and a preparation method thereof, pertaining to the field of herb tea which is drunk by smokers to abstain from cigarette addiction. The invention adopts 28 natural Chinese herbal medicines without any side effect, and can eliminate dependence on cigarettes by smokers with different degrees of cigarette addiction and smoking time so as to quit smoking within a few days without relapse. According to the mechanism of hard smoking addiction, the smoke abatement tea which is drunk by the smokers can firstly dissolve nicotine hormone in the blood and accelerate blood circulation and excretion so as to ensure that the smokers can get rid of the negative effect of the cigarette addiction; in addition, endorphin (EP) the secretion of which is stopped due to smoking by the smokers can be incited and secretes again after the smokers drink the smoke abatement tea, thus ensuring that the smokers can get rid of dependence on cigarettes and easily abstain from cigarette addiction with no requirement of relapse.

A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as an endorphin, enkephalin, dynorphin or endomorphin. Also detailed are processes for making the described conjugates and pharmaceutical compositions including such compounds.

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and / or nociceptin.

The invention provides smoking cessation tea and a preparation method thereof. Protospecies liu pao tea and five purely natural Chinese herbal medicines without side effect are adopted. The smoking cessation tea comprises the following components in parts by weight: 30-50 parts of liu pao tea, 8-12 parts of malt, 5-10 parts of pericarpium citri reticulatae, 10-13 parts of gypsum, 5-8 parts of elecampane and 10-15 parts of liquorice root. The components are prepared into a tea product with a conventional processing method. The smoking cessation tea has the function of removing body toxin, enhancing constitution and reducing dependence on smoke according to the mechanism of smoking addiction by the treatment principle of clearing heat, expelling toxin and righting qi in the traditional Chinese medicine. After a smoking quitter quits smoke, the tea can firstly decompose nicotine hormone in blood quickly to quicken blood circulation and excretion and get rid of psychological addiction troubles; then, endorphin (EP) which stops secreting in the body of the smoking quitter because of smoking is aroused to secrete again; and dependence on cigarettes can be fundamentally solved no matter how deep the smoking addiction degree is and how long the smoking year is so that the smoking addiction is easily quitted.

Methods and compositions for treating cancer and other disorders by β-endorphin therapy are disclosed.

The present invention provides a pharmaceutical composition that includes a) one or both of i) a peptide ligand that binds a zeta receptor and ii) at least one cancer chemotherapeutic agent; and b) a sustained release formulation. The invention also provides a combination including at least a portion of a tissue comprising one or more cells harboring a zeta receptor, such as a cancer cell or a precancerous cell, in contact with a pharmaceutical composition of the invention. Additionally the invention provides a method of treating a pathology that responds to a peptide ligand that binds a zeta receptor that includes a step of contacting a tissue characteristic of the pathology and containing cells harboring a zeta receptor, with a pharmaceutical composition of the invention. The invention further provides methods of inhibiting proliferation or metastasis of a cancer in a subject, including a) surgically excising a tumor characterizing the cancer from the subject; b) ensuring maximal removal of a tumor margin from the tumor site; and c) disposing a pharmaceutical composition of the invention upon a tissue remaining at a tumor margin wherein the tissue contains one or more tumor cells (such as a cancer cell or a precancerous cell) harboring a zeta receptor. The peptide ligand of a zeta receptor may be an enkephalin, an endorphin, a dynorphin, or a derivative thereof. Additionally the pharmaceutical composition may include one or more cancer chemotherapeutic agents.

A therapeutic formulation comprising a microemulsion of a therapeutic agent in free and / or conjugatively coupled form, wherein the microemulsion comprises a water-in-oil (w / o) microemulsion including a lipophilic phase and a hydrophilic phase, and has a hydrophilic and lipophilic balance (HLB) value between 3 and 7, wherein the therapeutic agent may for example be selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid honnone, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminease, adenosine deaminase, ribonuclease, trypsin, chymotrypsin, papain, Ara-A (Arabinofuranosyladenine), Acylguanosine, Nordeoxyguanosine, Azidothym id ine, Didesoxyadenosine, Dideoxycytidine, Dideoxyinosine Floxuridine, 6-Mercaptopurine, Doxorubicin, Daunorubicin, or I-darubicin, Erythromycin, Vancomycin, oleandomycin, Ampicillin; Quinidine and Heparin. In a particular aspect, the invention comprises an insulin composition suitable for parenteral as well as non-parenteral administration, preferably oral or parenteral administration, comprising insulin covalently coupled with a polymer including (i) a linear polyalkylene glycol moiety and (ii) a lipophilic moiety, wherein the insulin, the linear polyalkylene glycol moiety and the lipophilic moiety are conformationally arranged in relation to one another such that the insulin in the composition has an enhanced in vivo resistance to enzymatic degradation, relative to insulin alone. The microemulsion compositions of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Benzodiazepine withdrawal induced anxiety is treated by administration of an enkephalinase inhibitor, and a gamma-aminobutyric acid (“GABA”) precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the enkephalinase inhibitor D-phenylalanine, the GABA precursor glutamine, the serotonin precursor 5-HTP, glycine, and taurine, in combination with coenzymatic functionality of folic acid is preferred for activation of ligand-gated Cl− channel in the central nervous system. Food supplement embodiments provide the human body nutritional supplements to intake certain neurotransmitter precursor substrates, thereby enabling patients of all ages to self-regulate their ability to quell perturbations to equilibrium and simultaneously to adverse effects upon normal physiological and psychological functioning attributable to induced anxiety and panic associated with benzodiazepine withdrawal.

The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Provided is a caffeoyl-alpha-eoendrophin peptide derivative, and use thereof as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.

The invention relates to daily supplies, and particularly relates to bath foam. The bath foam is mainly prepared from the following components in percentage by weight: 3.0-10.0 percent of stearic acid, 6.0-12.0 percent of lauric acid, 7.5-10.0 percent of myristic acid, 4.0-8.0 percent of glycerinum, 1-2 percent of rosemary essential oil, 1.5-2.0 percent of monostearin, 0.8-2 percent of ylang-ylang essential oil, 4-7 percent of evening primrose essential oil, 2-5 percent of amyris essential oil and deionized water. The bath foam is capable of promoting fat metabolism, nourishing skin, resisting spasm, relieving pain, balancing nerves, resisting depression and exciting endorphin and serotonin to generate in a human body.

Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.

The invention relates to the field of canned food, in particular to a canned banana processing method. Bananas contain various trace elements and vitamins, vitamin A can promote growth, improve disease immunity and meets daily wants for reproduction and sight. Thiamine can resist beriberi, promote appetite, benefit digestion and protect the nervous system. Riboflavin can promote normal human growth and development. Bananas rich in potassium content and capable of balancing ill effects of sodium can treat hypertension and facilitate growth of cells and tissues. Bananas capable of facilitating peristalsis of intestines and stomach can treat constipation and can treat depression and emotional easiness due to capability of accelerating brain to secrete chemical substance endorphin. Since xylitol is added into the bananas, patients with diabetes and the middle and aged people also can take the canned bananas, so that the canned bananas are more natural and healthier.

The invention relates to a compound radix-angelicae-sinensis bletilla-gum emulsifiable paste for controlling intraoperative pressure sore and a nursing method thereof. The emulsifiable paste is a traditional Chinese medicine preparation with efficacy of tonifying blood and activating blood, and promoting tissue regeneration and wound healing. Cooperation of the compound radix-angelicae-sinensis bletilla-gum emulsifiable paste and employed electromagnetic spectrum mainly used to externally apply information and energy enables body internal organs to mutually balance, enables body to be coordinated and consistent with external environment, is capable of improving activity of enzyme in body, promoting absorption of body on various lack elements and restoring and dredging microcirculation channels, is capable of stimulating body self immunologic function and disease-resistant capability, and is capable of promoting secretion of body enkephalin and giving play to effects of easing pain, diminishing inflammation, promoting healing and the like. The compound radix-angelicae-sinensis bletilla-gum emulsifiable paste is cooperated with electromagnetic spectrum TDP (Teding Diancibo Pu) irradiation for controlling intraoperative pressure sore, operation is simple, usage is convenient, a patient has no pain and no adverse reaction, the effect satisfies, the cost is low, the adaptability is wide, the cost is only 1% of treatment cost, also the labor intensity of medical affairs is reduced, and complex operation for preventing pressure sore is simple and convenient.

A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as an endorphin, enkephalin, dynorphin or endomorphin. Also detailed are processes for making the described conjugates and pharmaceutical compositions including such compounds.

The inventive powder is made of ossified horns of reindeer and contains 25 pmol / g of endorphins in the form of agent for preventing and treating pathological states associated with endorphin deficiency in organism.

The Chinese medicine preparation for stopping drug addiction is prepared with nine kinds of Chinese medicinal materials including fresh aloe leaf, kendir leaf, cordate houttuynia, balloonflower root, etc. as well as honey and medicinal acceptable additive. It is prepared into oral liquid capsule, chewing gum and other forms. It can reduce the harm of drug, such as heroin, cocain, marijuana, etc. effectively, raise immunity, regulate endorphin system and prevent re-taking in drug.

The invention provides a smoke abatement tea and a preparation method thereof, pertaining to the field of herb tea which is drunk by smokers to abstain from cigarette addiction. The invention adopts 28 natural Chinese herbal medicines without any side effect, and can eliminate dependence on cigarettes by smokers with different degrees of cigarette addiction and smoking time so as to quit smoking within a few days without relapse. According to the mechanism of hard smoking addiction, the smoke abatement tea which is drunk by the smokers can firstly dissolve nicotine hormone in the blood and accelerate blood circulation and excretion so as to ensure that the smokers can get rid of the negative effect of the cigarette addiction; in addition, endorphin (EP) the secretion of which is stopped due to smoking by the smokers can be incited and secretes again after the smokers drink the smoke abatement tea, thus ensuring that the smokers can get rid of dependence on cigarettes and easily abstain from cigarette addiction with no requirement of relapse.

The inventive powder is made of ossified horns of reindeer and contains 25 pmol / g of endorphins in the form of agent for preventing and treating pathological states associated with endorphin deficiency in organism.

The present invention provides the use of Entauren in the preparation of drugs for detoxification, that is, a new application of Entaurea for drug withdrawal; Entaurea is widely used as an early analgesic for acute trauma As well as drugs in operations and other invasive medical operations that require a short analgesic time, they have the advantages of being safe, effective, simple, economical, non-invasive, and can replace narcotic analgesics. They can activate the central nervous system and promote endogenous The release of opioid peptides can supplement the lack of endorphins released by the body due to long-term drug use. Old drugs are used for new purposes, and the scope of application can be broadened as a drug detoxification drug. At the same time, Antaile can also relieve the pain caused by withdrawal symptoms and relieve anxiety. Reduce acute sudden death caused by severe withdrawal symptoms, so that drug addicts can stay awake, relaxed, comfortable and cooperate with treatment without pain during the entire detoxification treatment process.